Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Rublein

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2001
DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories)A H Corbett, J C Rublein
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 26, 1998
Evaluation of the use of nontraditional treatments by patients with HIVM A Dietrich, J C Rublein, J D Butts, et al.
The Annals of Pharmacotherapy|September 24, 1999
Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mgJ C Rublein, J J Eron, J D Butts, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2001
DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories)A H Corbett, J C Rublein
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 26, 1998
Evaluation of the use of nontraditional treatments by patients with HIVM A Dietrich, J C Rublein, J D Butts, et al.
The Annals of Pharmacotherapy|September 24, 1999
Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mgJ C Rublein, J J Eron, J D Butts, et al.
Pageof 1